A CRISPR/dCasX-mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c-MYC or activating TP53

Congcong Cao; Lin Yao; Aolin Li; Quan Zhang; Zhenan Zhang; Xiaofei Wang; Ying Gan; Yuchen Liu; Qian Zhang

doi:10.1002/ctm2.537

A CRISPR/dCasX-mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c-MYC or activating TP53

Clin Transl Med. 2021 Sep;11(9):e537. doi: 10.1002/ctm2.537.

Authors

Congcong Cao^{1

2

3

4

5

6}, Lin Yao^{1

2

3

4}, Aolin Li^{1

2

3

4}, Quan Zhang^{1

2

3

4}, Zhenan Zhang^{1

2

3

4}, Xiaofei Wang^{1

2

3

4}, Ying Gan^{1

2

3

4}, Yuchen Liu⁵, Qian Zhang^{1

2

3

4}

Affiliations

¹ Department of Urology, Peking University First Hospital, Beijing, China.
² Institute of Urology, Peking University, Beijing, China.
³ National Urological Cancer Center, Beijing, China.
⁴ Beijing Key Laboratory of Urogenital Diseases (male) Molecular Diagnosis and Treatment Center, Beijing, China.
⁵ Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Institute of Translational Medicine, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
⁶ Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen-Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
CRISPR-Cas Systems / genetics*
Cell Line, Tumor
Gene Editing / methods*
Humans
Mice
Proto-Oncogene Proteins c-myc / genetics*
Tumor Suppressor Protein p53 / genetics*
Urinary Bladder Neoplasms* / genetics
Urinary Bladder Neoplasms* / therapy

Substances

Proto-Oncogene Proteins c-myc
TP53 protein, human
Tumor Suppressor Protein p53

Publication types

MeSH terms

Substances

Grants and funding